Seres Therapeutics
MCRB
89 hedge funds and large institutions have $308M invested in Seres Therapeutics in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 18 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
3.85% more ownership
Funds ownership: 0% → 3.85% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 94 → 89 (-5)
19% less capital invested
Capital invested by funds: $382M → $308M (-$74.2M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
46% less call options, than puts
Call options by funds: $292K | Put options by funds: $544K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.45M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$2.44M |
| 3 |
AG
Artal Group
Luxembourg
|
+$2.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.25M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.2M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$4.35M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.19M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.92M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.64M |
MCRB Hedge Fund Activity: Q4 2016 in Review
89 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2016, worth a combined $308M — down 19% from $382M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MCRB and 13 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 37 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.45M. The largest seller was Federated Hermes, cutting an estimated $10.2M.
- 89 institutional investors held Seres Therapeutics (MCRB) as of Q4 2016, down from 94 in Q3 2016.
- Funds reported $308M of Seres Therapeutics stock for Q4 2016, down 19% quarter-over-quarter.
- 13 funds opened new Seres Therapeutics positions in Q4 2016 and 18 closed out, a net change of -5 holders.
- The largest Seres Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $2.45M added.
- The largest Seres Therapeutics seller in Q4 2016 was Federated Hermes, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2016.